SHINE Medical Technologies has filed an application with the U.S. Nuclear Regulatory Commission to produce medical isotopes at its production facility in Janesville, Wis., the company announced today.

“Completing our NRC operating license application signals the transition of our efforts to establish a secure global supply of medical isotopes from the design and engineering phase to the construction and delivery phase,” SHINE CEO Greg Piefer said in a statement.

According to a release, the isotopes that will be produced are molybdenum-99 (Mo-99), iodine-131 and xenon-133.

SHINE broke ground on its facility in May.